Interesting ZYME Put And Call Options For March 20th

Zymeworks (ZYME) is trading at $23.54; selling a $17.50 put (bid $0.20) would obligate purchase at $17.50 with an effective cost basis of $17.30, is ~26% out-of-the-money, carries an 81% modeled probability of expiring worthless and would yield 1.14% (6.63% annualized) if it does. Alternatively, selling a $25.00 covered call (bid $0.10) against shares bought at $23.54 would cap proceeds at $25 and deliver a 6.63% total return if called by the March 20 expiration, with a 50% modeled chance of expiring worthless and a 0.42% premium boost (2.46% annualized); implied vols are 61% (put) and 78% (call) versus a trailing 12-month volatility of 56%.

Analysis

Market structure: The immediate mechanics favor option sellers and patient buyers. Selling the Mar 20 ZYME 17.50 put (bid $0.20) converts a potential purchase at $17.50 into an effective cost basis of $17.30 — ~26% below the $23.54 market price — and offers a short-term yieldBoost of 1.14% (6.63% annualized). Implied vols (puts 61%, calls 78%) exceed trailing realized vol (56%), signaling short-term demand for directional exposure and asymmetric upside hedging in the chain rather than broad market stress.

Risk assessment: Tail risk is dominated by binary biotech outcomes (trial/regulatory news) that can gap >30% intraday; assignment risk and poor liquidity in ZYME options are real second-order threats. Timeframe matters — this is a short-dated (Mar 20) trade: days-to-weeks risk is option-gamma and news sensitivity, while quarters-years risk ties to pipeline readouts and cash runway. Watch IV skew — if call IV stays >20 pts above realized, upside demand could abruptly compress or spike around catalysts.

Trade implications: Implement cash-secured short puts to target a 26% lower basis or use covered calls to monetize a long position; for active volatility play, sell the Mar 20 17.50 put or sell/roll 25 covered calls if assigned. Prefer defined-risk put spreads (sell 17.5/15) to limit assignment while collecting premium; avoid naked short calls given IV and binary upside. Size trades small (1–3% NAV) given event risk and limited premium.

Contrarian angles: The market’s 81% “expire worthless” put probability may underprice negative clinical outcomes — implied skew suggests retail/hedge demand for upside protection, not fundamentals. If you believe fundamentals are stable and no near-term binary, selling volatility (short put or covered call) is likely underpriced versus realized vol; conversely, if you expect a catalyst drop >25%, these short premium plays are mispriced and risky. Historical biotech option mispricings resolve quickly around readouts; plan tight rules for roll/cover at +/-10–15% moves.

Key Decisions for Investors

• Establish a small (1–3% NAV) cash-secured short position: sell-to-open ZYME Mar20 17.50 puts for $0.20 (effective buy at $17.30). Close or roll if ZYME > $22 by Mar 10, or buy back if ZYME < $16 (cut loss) or IV rises >30 pts.
• If already long ZYME at or above $23.54, sell Mar20 25.00 calls at $0.10 to create a covered call (boost +0.42%). Allow assignment to realize ~6.63% total if called; buy to close if stock > $26 or IV drops >15 pts.
• If concerned about binary downside, enter a defined-risk put spread: sell Mar20 17.50 / buy Mar20 15.00 put spread size to limit max drawdown. Target net credit >$0.05 and cap loss to known amount; exit if spread widens >3x credit.
• Do NOT buy outright shares at $23.54 as primary entry if target basis is $17–18; instead use the cash-secured put strategy to acquire at preferred price within next ~2 months (Mar 20 expiration).
• Monitor catalysts daily: any clinical/regulatory filing or material press within 30 days should trigger immediate reassessment; if a readout is scheduled within 14 days, close short-dated premium positions and reduce exposure to <0.5% NAV.